AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ANIMALCARE GROUP PLC

Regulatory Filings Jul 9, 2018

7488_rns_2018-07-09_a21e330a-0589-404a-b622-8a05da001ad1.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9706T

Animalcare Group PLC

09 July 2018

09 July 2018

Animalcare Group plc

("Animalcare", the "Company" or the "Group")

Cortacare recommended for European marketing approval by CVMP

-      Launch in European markets expected in Q4 2018

-      Expands Animalcare's dermatology portfolio

Animalcare Group plc (AIM:ANCR), the pan-European animal health business, today announces that it has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), recommending European marketing authorisation for its dermatology product Cortacare. Animalcare plans to launch Cortacare in Q4 2018 through its direct sales operations in seven European countries and international distribution network.

Cortacare is a wholly-owned product, developed by Animalcare as a cutaneous spray for the treatment of inflammatory and pruritic dermatitis in dogs. The product is a corticosteroid designed to be applied topically to reduce inflammation and itching, which complements Animalcare's existing dermatology portfolio. Cortacare accumulates in the dog's skin, allowing for high local activity whilst minimising side effects, and leading to an improvement of skin lesions associated with the condition.

Chris Cardon, CEO of Animalcare Group plc, commented:

"As part of the reprioritisation of our product development pipeline we identified 17 core development products. We are pleased to see the first of these receive a positive recommendation from the CVMP, which paves the way for the commercialisation of this wholly owned product across Europe and expands our existing dermatology portfolio. Product development remains a key area for us and we are focused on building value within our development pipeline. We look forward to announcing further success as the pipeline progresses."     

Enquiries:

Animalcare Group plc
Chris Cardon, Chief Executive Officer Tel: 01904 487 687
Chris Brewster, Chief Financial Officer
Panmure Gordon (UK) Ltd (Nominated Adviser & Broker) Tel: 020 7886 2500
Corporate Finance
Freddy Crossley / Peter Steel
Corporate Broking
James Stearns
Consilium Strategic Communications Tel: 020 3709 5700
Amber Fennell animalcare@consilium-comms.com
Chris Welsh
Olivia Manser

About Animalcare Group plc

Animalcare is a pan-European sales, marketing and product development company focused on the veterinary and animal health sectors. The Company has operations across Europe with direct sales in seven countries (UK, Belgium, Netherlands, Spain, Portugal, Italy and Germany), and exports to approximately 40 markets worldwide through global partnerships. The Company sells over 300 products including pharmaceuaticals, vaccines and  nutraceuticals . Animalcare has a diverse pipeline of products in development and a strong network of distribution and in-license partnerships. For more information, please visit: www.animalcaregroup.co.uk 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

NRAFVLLBVDFZBBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.